Page 7 - Cash Inflow News Today : Breaking News, Live Updates & Top Stories | Vimarsana

  AstraZeneca delivered strong results in the year, in line with guidance that was reconfirmed during the year. With over half of Total Revenue coming from the fast-growing new medicines 1, the Company leveraged its revenue growth to make further progress in profitability, while the strategy of sustainable growth through innovation brought numerous further benefits for patients. AstraZeneca s patient-centric strategy, focus on innovation and capital-allocation priorities remain unchanged, with sustainable long-term growth in revenue, profit and cash generation set to continue.   Pascal Soriot, Chief Executive Officer, commented: The performance last year marked a significant step forward for AstraZeneca. Despite the significant impact from the pandemic, we delivered double-digit revenue growth to leverage improved profitability and cash generation. The consistent achievements in the pipeline, the accelerating performance of our business and the progress of the COVID-19

United statesUnited kingdomPascal soriotInternational financial reporting standardsStrategic advisory group of experts on immunizationUniversity of oxfordVaccines allianceWorld health organizationCoalition for epidemic preparedness innovationsGroup financialMerck co incNational reimbursement drug listShareaction workforce disclosure initiativeEuropean medicines agencyHealthcare products regulatory agencyCompany of alexion pharmaceuticals inc